Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on treatment with anti-EGFR-based therapy can be resista...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.946850/full |
| _version_ | 1797935438635204608 |
|---|---|
| author | Chiara Cremolini Clara Montagut Philippe Ronga Filippo Venturini Kensei Yamaguchi Sebastian Stintzing Alberto Sobrero |
| author_facet | Chiara Cremolini Clara Montagut Philippe Ronga Filippo Venturini Kensei Yamaguchi Sebastian Stintzing Alberto Sobrero |
| author_sort | Chiara Cremolini |
| collection | DOAJ |
| description | In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on treatment with anti-EGFR-based therapy can be resistant to further anti-EGFR treatment, but evidence suggests that the anti-EGFR-resistant clones decay, thereby opening the potential for rechallenge or reintroduction in later lines of treatment. Results from recent clinical studies have shown that some patients with mCRC who are rechallenged with anti-EGFR monoclonal antibodies exhibit durable responses. While other therapies have demonstrated improved overall survival in chemorefractory mCRC over the past decade, rechallenge with anti-EGFR monoclonal antibodies in later lines of treatment represents a new option that deserves further investigation in clinical trials. In this review, we summarize the molecular rationale for rechallenge or reintroduction in patients with mCRC who have progressed on earlier-line anti-EGFR treatment and examine the current evidence for using liquid biopsy as a method for selecting rechallenge as a therapeutic option. We also provide an overview of published trials and trials in progress in this field, and outline the potential role of rechallenge in the current clinical setting. |
| first_indexed | 2024-04-10T18:15:31Z |
| format | Article |
| id | doaj.art-1777e610457b4d03857d820d434f40e8 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T18:15:31Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1777e610457b4d03857d820d434f40e82023-02-02T09:02:04ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-02-011210.3389/fonc.2022.946850946850Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancerChiara Cremolini0Clara Montagut1Philippe Ronga2Filippo Venturini3Kensei Yamaguchi4Sebastian Stintzing5Alberto Sobrero6Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, ItalyDepartment of Medical Oncology, Hospital del Mar— Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, SpainGlobal Medical Affairs, Merck Healthcare KGaA, Darmstadt, GermanyGlobal Medical Affairs, Merck Serono S.p.A., an Affiliate of Merck KGaA, Rome, ItalyDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Hematology, Oncology, and Cancer Immunology (CCM), Charité–Universitätsmedizin, Berlin, GermanyDepartment of Medical Oncology, Ospedale San Martino, Genoa, ItalyIn patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on treatment with anti-EGFR-based therapy can be resistant to further anti-EGFR treatment, but evidence suggests that the anti-EGFR-resistant clones decay, thereby opening the potential for rechallenge or reintroduction in later lines of treatment. Results from recent clinical studies have shown that some patients with mCRC who are rechallenged with anti-EGFR monoclonal antibodies exhibit durable responses. While other therapies have demonstrated improved overall survival in chemorefractory mCRC over the past decade, rechallenge with anti-EGFR monoclonal antibodies in later lines of treatment represents a new option that deserves further investigation in clinical trials. In this review, we summarize the molecular rationale for rechallenge or reintroduction in patients with mCRC who have progressed on earlier-line anti-EGFR treatment and examine the current evidence for using liquid biopsy as a method for selecting rechallenge as a therapeutic option. We also provide an overview of published trials and trials in progress in this field, and outline the potential role of rechallenge in the current clinical setting.https://www.frontiersin.org/articles/10.3389/fonc.2022.946850/fullmetastatic colorectal cancer (mCRC)anti-EGFRrechallengereintroductionliquid biopsy |
| spellingShingle | Chiara Cremolini Clara Montagut Philippe Ronga Filippo Venturini Kensei Yamaguchi Sebastian Stintzing Alberto Sobrero Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer Frontiers in Oncology metastatic colorectal cancer (mCRC) anti-EGFR rechallenge reintroduction liquid biopsy |
| title | Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer |
| title_full | Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer |
| title_fullStr | Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer |
| title_full_unstemmed | Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer |
| title_short | Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer |
| title_sort | rechallenge with anti egfr therapy to extend the continuum of care in patients with metastatic colorectal cancer |
| topic | metastatic colorectal cancer (mCRC) anti-EGFR rechallenge reintroduction liquid biopsy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.946850/full |
| work_keys_str_mv | AT chiaracremolini rechallengewithantiegfrtherapytoextendthecontinuumofcareinpatientswithmetastaticcolorectalcancer AT claramontagut rechallengewithantiegfrtherapytoextendthecontinuumofcareinpatientswithmetastaticcolorectalcancer AT philipperonga rechallengewithantiegfrtherapytoextendthecontinuumofcareinpatientswithmetastaticcolorectalcancer AT filippoventurini rechallengewithantiegfrtherapytoextendthecontinuumofcareinpatientswithmetastaticcolorectalcancer AT kenseiyamaguchi rechallengewithantiegfrtherapytoextendthecontinuumofcareinpatientswithmetastaticcolorectalcancer AT sebastianstintzing rechallengewithantiegfrtherapytoextendthecontinuumofcareinpatientswithmetastaticcolorectalcancer AT albertosobrero rechallengewithantiegfrtherapytoextendthecontinuumofcareinpatientswithmetastaticcolorectalcancer |